Pharma Focus Asia

Almac Group invests £16 million for expansion in pharmaceutical development capacity in Loughborough, England


Craigavon-based Almac Group has announced an  £16 million investment to expand its formulation and analytical development services to meet ongoing client demand.


The company announced the successful conclusion to negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England – a world-class science, technology and enterprise park.  Specifically, Almac will occupy the formulation development and analytical testing facilities at the site which will complement existing development & GMP services offered from its Craigavon NI Headquarters.

The Charnwood facilities were originally designed and built by a global Pharma company as part of its in-house formulation development, clinical manufacturing & analytical testing capabilities. Almac has now commenced recommissioning of the facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing, creating approximately 180 new jobs in the next 5 years.


NameAlmac Group
LocationLoughborough, England
Estimated Cost£16 Million
Jobs180 Jobs
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference